Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about GR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No summary available yet.
No AI portrait yet
| Name | GR |
| Key Genes/Proteins | AGER, AKT, ALS, AR, BAG3, BDNF |
| Related Diseases | Alzheimer's disease |
| Related Pathways | apoptosis pathway, autophagy pathway, CRISPR-Cas |
| Linked Hypotheses | 2 hypotheses |
Knowledge base pages for this entity
graph TD
GR[GR]
GR -->|regulates| Glioblastoma[Glioblastoma]
GR -->|mediates| Memory_Impairment[Memory Impairment]
GR -.protects against.-> Ferroptosis[Ferroptosis]
GR -->|regulates| Microglial_Activation[Microglial Activation]
GR -->|contributes to| Glutamate_Excitotoxicity[Glutamate Excitotoxicity]
GR -->|contributes to| Oxidative_Stress[Oxidative Stress]
GR -->|regulates| HPA_AXIS[HPA_AXIS]
GR -->|regulates| TUMOR_GROWTH[TUMOR_GROWTH]
GR -->|interacts| P38[P38]
GR -->|activates| NLRP3[NLRP3]
Mifepristone[Mifepristone] -->|inhibits| GR
RU486[RU486] -->|inhibits| GR
Corticosterone[Corticosterone] -->|activates| GR
EIF4G2[EIF4G2] -->|interacts| GR
FERROPTOSIS[FERROPTOSIS] -->|inhibits| GR
DNA[DNA] -->|activates| GR
SKA2[SKA2] -->|regulates| GR
C9ORF72[C9ORF72] -->|interacts| GR
AKT[AKT] -->|activates| GR
GCLC[GCLC] -->|activates| GR| Target | Relation | Type | Str |
|---|---|---|---|
| Glioblastoma | regulates | disease | 0.95 |
| Ferroptosis | protects_against | process | 0.85 |
| Memory Impairment | mediates | phenotype | 0.85 |
| Microglial Activation | regulates | process | 0.80 |
| Glutamate Excitotoxicity | contributes_to | process | 0.75 |
| Oxidative Stress | contributes_to | process | 0.75 |
| HPA_AXIS | regulates | pathway | 0.72 |
| frontotemporal dementia | associated_with | disease | 0.70 |
| TUMOR_GROWTH | regulates | phenotype | 0.64 |
| neuroinflammation | inhibits | disease | 0.60 |
| autophagy pathway | participates_in | pathway | 0.60 |
| neurodegeneration | regulates | disease | 0.60 |
| LDH | biomarker_for | gene | 0.60 |
| ferroptosis | participates_in | pathway | 0.60 |
| SRRM2 | associated_with | gene | 0.60 |
| NR3C1 | regulates | gene | 0.60 |
| NR3C1 | associated_with | gene | 0.60 |
| NFL | expressed_in | gene | 0.60 |
| neurodegeneration | expressed_in | disease | 0.60 |
| NFL | causes | gene | 0.60 |
| neurodegeneration | associated_with | disease | 0.60 |
| frontotemporal dementia | activates | disease | 0.60 |
| HSC70 | regulates | gene | 0.60 |
| GSH | biomarker_for | gene | 0.60 |
| NQO1 | inhibits | gene | 0.60 |
| apoptosis pathway | participates_in | pathway | 0.60 |
| neurodegeneration | activates | disease | 0.60 |
| HSP70 | regulates | gene | 0.60 |
| HSPA1A | regulates | gene | 0.60 |
| HSPA8 | regulates | gene | 0.60 |
| SQSTM1 | regulates | gene | 0.60 |
| STUB1 | regulates | gene | 0.60 |
| VCP | regulates | gene | 0.60 |
| LC3 | associated_with | gene | 0.60 |
| SQSTM1 | associated_with | gene | 0.60 |
| pyroptosis | participates_in | pathway | 0.60 |
| oxidative stress response | participates_in | pathway | 0.60 |
| glioblastoma | activates | disease | 0.60 |
| glioblastoma | expressed_in | disease | 0.60 |
| ubiquitin-proteasome | participates_in | pathway | 0.60 |
| Alzheimer's disease | associated_with | disease | 0.60 |
| NAD | inhibits | gene | 0.60 |
| CRISPR-Cas | participates_in | pathway | 0.60 |
| microglia | expressed_in | cell_type | 0.60 |
| macrophages | expressed_in | cell_type | 0.60 |
| ROS | activates | gene | 0.60 |
| NR3C2 | associated_with | gene | 0.60 |
| P38 | interacts_with | gene | 0.60 |
| RNA | activates | gene | 0.60 |
| NLRP3 | activates | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| RU486 | inhibits | drug | 0.95 |
| Mifepristone | inhibits | drug | 0.95 |
| Corticosterone | activates | compound | 0.85 |
| EIF4G2 | interacts_with | gene | 0.80 |
| FERROPTOSIS | inhibits | process | 0.80 |
| ALS | associated_with | gene | 0.70 |
| DNA | activates | gene | 0.70 |
| SKA2 | regulates | gene | 0.64 |
| GBM | expressed_in | gene | 0.60 |
| AR | inhibits | gene | 0.60 |
| ALS | activates | gene | 0.60 |
| FSP1 | inhibits | gene | 0.60 |
| GBM | activates | gene | 0.60 |
| BAG3 | regulates | gene | 0.60 |
| CALR | regulates | gene | 0.60 |
| BDNF | expressed_in | gene | 0.60 |
| BDNF | regulates | gene | 0.60 |
| BDNF | activates | gene | 0.60 |
| BECN1 | associated_with | gene | 0.60 |
| DHFR | inhibits | gene | 0.60 |
| DNA | interacts_with | gene | 0.60 |
| GFP | interacts_with | gene | 0.60 |
| C9ORF72 | interacts_with | gene | 0.60 |
| AKT | activates | gene | 0.60 |
| GCLC | activates | gene | 0.60 |
| AGER | associated_with | gene | 0.50 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| GWAS of plasma NfL in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma pTau217 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| Dairy intake and dementia risk in Malmö Diet and Cancer cohort | clinical | Alzheimer's disease | 0.950 | 0.00 | Swedish community-based adults | proposed | N/A |
| GWAS of plasma pTau181 in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| GWAS of plasma GFAP in East Asian cohort | exploratory | Alzheimer's disease | 0.950 | 0.00 | human patients - East Asian co | proposed | N/A |
| KEEPS Continuation: Long-term effects of menopausal hormone therapy on | clinical | Alzheimer's disease | 0.950 | 0.00 | recently menopausal women with | proposed | N/A |
| GWAS of composite biomarker score | exploratory | Alzheimer's disease | 0.900 | 0.00 | human patients - East Asian co | proposed | N/A |
| RBG treatment in ApoE-/- atherosclerosis mouse model | validation | atherosclerosis | 0.900 | 0.00 | ApoE-/- mice | proposed | N/A |
| Chi3l1 deletion effects on baseline glial activation in mice | validation | baseline neuroinflammation | 0.900 | 0.00 | Chi3l1 knockout mice | proposed | N/A |
| CHI3L1 variant association with AD progression in human patients | exploratory | Alzheimer's disease | 0.850 | 0.00 | human patients | proposed | N/A |
| s:** - Biochemical binding assays measuring PROTAC selectivity for APO | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $100,000 |
| Why Does Amyloid Removal Only Slow Decline 27%? — Mechanistic investig | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $7,100,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegenerat [PMID:37995685] | Litvinchuk A, Suh JH, Guo JL, Lin K, Dav | Neuron | 2024 | 1 |
| The cell biology of APOE in the brain. [PMID:37805344] | Windham IA, Cohen S | Trends Cell Biol | 2024 | 1 |
| The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegene [PMID:37957317] | Maxine R Nelson, Peng Liu, Ayushi Agrawa | Nature neuroscience | 2023 | 1 |
| APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therape [PMID:33340485] | Serrano-Pozo A, Das S, Hyman BT | Lancet Neurol | 2021 | 1 |
| Lysosome-targeting chimaeras for degradation of extracellular proteins. [PMID:32728216] | Banik SM, Pedram K, Wisnovsky S, Ahn G, | Nature | 2020 | 1 |
| Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. [PMID:31564456] | Long JM, Holtzman DM | Cell | 2019 | 1 |
| Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. [PMID:31367008] | Yamazaki Y, Zhao N, Caulfield TR, Liu CC | Nat Rev Neurol | 2019 | 1 |
| Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associate [PMID:41905188] | Cetindag AC, Schipke CG, Esselmann H, Kr | The journal of prevention of A | 2026 | 0 |
| Perioperative polygenic and APOE-based genetic risk assessment for neurocognitiv [PMID:40562635] | Thedim M, Hu J, Maher M, Wiener-Kronish | Br J Anaesth | 2026 | 0 |
| Increased genetic protection against Alzheimer's disease in centenarians. [PMID:40615639] | Bae H, Song Z, Ali A, Sasaki T, Tesi N e | Geroscience | 2026 | 0 |
| Monocyte LOXHD1 and RHOB Expression Predictive of Progressive Systemic Sclerosis [PMID:40771159] | Padilla CM, Lafyatis R, Gibson KF, Morse | Arthritis Care Res (Hoboken) | 2026 | 0 |
| Integrative machine learning approach to risk prediction for dementia and Alzhei [PMID:40864401] | Stern A, Linial M | Geroscience | 2026 | 0 |
| Adipose Tissue Macrophage-Derived Proplatelet Basic Protein Exacerbates Psoriasi [PMID:40886963] | Zhu L, Du L, Wu J, Ding D, Wang J et al. | J Invest Dermatol | 2026 | 0 |
| Restoration of p53 mRNA combined with BRD4 silencing by brain targeted nanocapsu [PMID:41101204] | Sang Y, Cao Y, Li S, Quan Y, Wang S et a | Biomaterials | 2026 | 0 |
| Targeting KAT8 alleviates vascular senescence by modulating the INHBA/TGF-β path [PMID:41445196] | Lin Z, Xiong J, Zhang F, Zhang H, Zhu M | Mol Ther | 2026 | 0 |
| Obstructive sleep apnea, biomarker profiles, and clinical progression in Parkins [PMID:41499940] | Zhu S, An D, Liu X | Sleep Med | 2026 | 0 |
| Menopause, cognition, and Alzheimer's disease risk. [PMID:41531227] | Samudra N, Vemuri M, Weitlauf J | Curr Opin Obstet Gynecol | 2026 | 0 |
| Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystat [PMID:41576952] | Li X, Tang X, Zeng J, Duan L, Hou Z et a | Cell | 2026 | 0 |
| SuPAR levels are increased in sera of euthymic patients with bipolar disorder an [PMID:41605346] | Kök Kendirlioğlu B, Çörekli Kaymakçı E, | J Affect Disord | 2026 | 0 |
| Chitinase-like Proteins YKL-40 and YKL-39 in Colorectal Cancer. [PMID:41677627] | Ivanova T, Kazakova M, Dikov D, Dzhambov | Cells | 2026 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning GR in their description or question text
Score: 0.784 · neurodegeneration · 2026-04-15
## Mechanistic Overview Integrated Biomarker Panel for Therapeutic Window Identification starts from the claim that modu
Score: 0.784 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop tACS targeting entorhinal cortex layer II SST interneurons to activate AMPK-autophag
Score: 0.776 · neurodegeneration · 2026-04-16
## Mechanistic Overview CX3CR1-TREM2 Integration for Synapse Pruning Normalization starts from the claim that modulating
Score: 0.748 · neurodegeneration · 2026-04-12
**Molecular Mechanism and Rationale** The TREM2-CSF1R metabolic cross-talk hypothesis centers on the intricate molecula
Score: 0.737 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The central molecular mechanism underlying this hypothesis involves the intricate
Score: 0.735 · neurodegeneration · 2026-04-22
**Molecular Mechanism and Rationale** The NAD+/SIRT3 axis represents a critical regulatory hub controlling mitochondria
Score: 0.734 · neurodegeneration · 2026-04-15
## Mechanistic Overview SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysosomal Degradation via Autophagosome-Ly
Score: 0.730 · biomarkers · 2026-04-22
## Mechanistic Overview Integrated Multi-Analyte CSF Panel Combining YKL-40, sTREM2, and Neurogranin starts from the cla
Score: 0.727 · neurodegeneration · 2026-04-02
## Mechanistic Overview Synthetic Biology BBB Endothelial Cell Reprogramming starts from the claim that modulating TFR1,
Score: 0.725 · neurodegeneration · 2026-04-02
## Mechanistic Overview TFAM overexpression creates mitochondrial donor-recipient gradients for directed organelle traff
Score: 0.720 · neurodegeneration · 2026-04-02
## Mechanistic Overview Stress Granule Phase Separation Modulators starts from the claim that modulating G3BP1 within th
Score: 0.718 · neurodegeneration · 2026-04-12
## Mechanistic Overview Disease-Associated Microglia Metabolic Reprogramming starts from the claim that modulating TREM2
Score: 0.717 · neurodegeneration · 2026-04-22
## **Molecular Mechanism and Rationale** The hexanucleotide repeat expansion (GGGGCC) in the C9orf72 gene represents th
Score: 0.710 · neurodegeneration · 2026-04-21
## **Molecular Mechanism and Rationale** The liquid-to-solid phase transition of ribonucleoprotein (RNP) granules repre
Score: 0.708 · neurodegeneration · 2026-04-02
## Mechanistic Overview Membrane Cholesterol Gradient Modulators starts from the claim that modulating ABCA1/LDLR/SREBF2